Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INI-822 in Healthy Volunteers and Participants With MASH
NCT05945537Phase 1Recruiting
- Sponsor
- Inipharm
- Start
- Sep 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing A (INI-822) with B (Placebo) (2 arms). Primary endpoints: Incidence of adverse events up to 12 weeks and Number of participants with clinical laboratory abnormalities up to 12 weeks. Started Sep 2023; status: recruiting.
02
Drugs
ini-822
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT05945537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945537.